Examination of efficacy of tolvaptan for chronic congective heart failure complicated with chronic kidney disease.

Not Applicable

Recruiting

• Conditions: Chronic congestive heart failure

• Registration Number: JPRN-UMIN000014312
• Lead Sponsor: Department of Cardiology, Gifu University Graduate School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-07-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who had acute myocardial infarction within 30 days . Patients of active myocarditis or the amyloid cardiomyopathy. Patients who are supported by circulation device. Patients who had decrease in circulation blood volume. Patients with hypertrophic cardiomyopathy (except the expansion aspect). Patients with severe valvular disease. Patients with hepatogenic comatose. Patients with insufficient treatment on diabetes mellitus. Patients whose blood pressure is less than 90mmHg. Patients that following electrolytes abnormality is accepted. Serum Na>147mEq/L, serum K>5.5mEq/L Patients who cannot take oral formulation. Patients with a pregnant woman, a nursing girl, pregnant possibility or the intention to become pregnant. Patients that are recognized as inappropriate for this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement effect of the heart failure

Secondary Outcome Measures

Name	Time	Method
BNP, renin activity, aldosteron, catecholamine, CRE, cystatin C, urine L-FABP